Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
Status:
Terminated
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This single-arm phase II study aims to study the efficacy of a possible first line treatment
that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with
concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with
active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this
new combinational therapy can benefit short-term and long-term survival of the patients with
advanced NSCLC.